Using Night-time Blood Pressure to Treat Hypertension

NCT ID: NCT05031637

Last Updated: 2024-05-02

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: NA
• Total Enrollment: 78 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2022-05-01
• Study Completion Date: 2024-02-28

Brief Summary

Objectives: To examine the feasibility of conducting night-time home blood pressure(BP) monitoring (during sleep) and titration of medications in the evening. This will provide data for sample size calculation for the main trial, which will examine whether night-time BP is a better target than conventional daytime BP for hypertension management.

Hypothesis to be tested: night-time home BP monitoring(HBPM) and evening drug titration are acceptable to patients; and future main trial is feasible in terms of recruitment/dropout rate/medication adherence.

Design and subjects: This pilot randomized-controlled trial will recruit 78 patients with nocturnal hypertension (asleep systolic BP 120mmHg on ambulatory blood pressure monitoring(ABPM)). They will be allocated in 1:1 ratio to have their medication titrated in the evening according to night HBPM (Experimental group) or in the morning according to daytime HBPM (control group) respectively.

Instruments: ABPM/HBPM. Interventions: titration of the dose(s) of anti-hypertensive medications in the evening according to night HBPM (experimental group) and in the morning according to daytime HBPM (control group) every 4 weeks.

Main outcome measures: ABPM at baseline and at 6 months Data analysis and expected results: The rate of recruitment/dropout and adherence to night HBPM will be presented. The feasibility of HBPM will be assessed by the patients' adherence to HBPM and by patients' interviews. ANCOVA will be used to evaluate whether titration of medication can normalize BP levels. We expect patients to have a high adherence rate and that titration of evening doses of medications will better improve night-time BP on ABPM.

Conditions

Hypertension

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: SINGLE

Study Groups

treatment by night-time BP

titrate drug treatment in the evening against night home blood pressure monitoring (HBPM) SBP (aiming SBP of \<120 mmHg; intervention group)

Group Type: EXPERIMENTAL

treatment of BP by using night-time BP

Intervention Type: BEHAVIORAL

titration of BP medications to target according to night-time SBP

treatment by daytime BP

Usual care - titrate drug treatment in the morning against HBPM SBP (aiming SBP of \<135 mmHg; control group)

Group Type: OTHER

treatment of BP by using daytime BP

Intervention Type: BEHAVIORAL

titration of BP medications to target according to daytime SBP

Interventions

treatment of BP by using night-time BP

titration of BP medications to target according to night-time SBP

Intervention Type: BEHAVIORAL

treatment of BP by using daytime BP

titration of BP medications to target according to daytime SBP

Intervention Type: BEHAVIORAL

Eligibility Criteria

Inclusion Criteria

• diagnosed hypertension (HT) from clinical records
• nocturnal HT (night-time systolic blood pressure (SBP) during sleep ≥120 mmHg) and stage I hypertension (daytime SBP = 135-159mmHg)

Exclusion Criteria

• patients with atrial fibrillation (many home blood pressure (BP) machines are not validated in these patients and these patients have greater BP variability)
• daytime office systolic BP ≥180 mmHg or diastolic BP ≥120 mmHg (regardless of nocturnal BP) because these patients need urgent BP treatment and it is not known if medications given in the evening are equally effective
• patients with known obstructive sleep apnoea because the night-time BP of these patients is predominately affected by the sleep apnoea
• patients with known stroke, ischemic heart disease, heart failure, kidney failure, peripheral vascular disease and diabetes mellitus because their daytime BP targets will be different
• dementia or psychiatric illness that impairs patients' ability to perform home blood pressure monitoring (HBPM) by themselves
• patients with end-stage malignancies
• nocturnal worker, because they will have a reverse BP pattern to other participants
• patients who sleep after 2am or wake up before 4am because these patients will not be asleep during night HBPM
• patients receiving ≥3 BP medications at maximal tolerated doses because there is little space for drug titration and these patients may have secondary HT representing another disease spectrum
• patients receiving anti-coagulants because ABPM can induce significant bruises (during repeated cuff inflations) in these patients.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Chinese University of Hong Kong

OTHER

Sponsor Role: lead

Responsible Party

Lee Kam Pui

Clinical Assistant Professor

Responsibility Role: PRINCIPAL_INVESTIGATOR

Locations

School of public health and primary care

Hong Kong, , Hong Kong

Countries

Hong Kong

Other Identifiers

2021.253-T

Identifier Type: -

Identifier Source: org_study_id